Medical technology company Nemaura Medical Inc (NASDAQ:NMRD) said on Wednesday that it has issued a presentation outlining the effective use of continuous glucose monitoring (CGM) in COVID-19 patients.

According to Nemaura, CGM has been used as an effective tool for the monitoring of disease progression in both quarantined and hospitalised COVID-19 patients. This includes improvement in glycaemic control in persons with Type 2 diabetes, monitoring and managing hyperglycaemia in patients with COVID-19, and remote monitoring of glucose levels in hospitalised COVID-19 patients leading to improved quality of care without compromising the safety of medical professionals.

The presentation is available at: https://nemauramedical.com/wp-content/uploads/2020/08/Glucose-monitoring-in-Covid19-August.pdf.